Cardiovascular Drugs Do Not Impact COVID-19 Outcomes
Authors say patients even with COVID-19 should continue taking cardiovascular drugs as prescribed
Hypertension
ACE Inhibitors vs ARBs for First-Line Hypertension Treatment
Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the treatment of hypertension according to US and European guidelines.
Intensive BP Control After ICH May Be Risky for CKD Patients
Intensive BP lowering after intracerebral hemorrhage linked to poorer outcomes in patients with decreased renal function
Prior Statin Use Linked to Reduced Risk for Death in COVID-19
Risk for death significantly reduced with prior statin and/or antihypertensive use among those with history of CVD and/or hypertension
Cognitive Decline May Be Slower With Blood-Brain Barrier Crossing Antihypertensive Drugs
Researchers assessed the ability of antihypertensive drugs to cross the blood-brain barrier.
COVID-19 Increases Health Inequities in Patients With Hypertension
This report draws on the work of several sources, including a diverse group of experts at a recent conference that discussed health inequities magnified by the COVID-19 pandemic.
Certain Antihypertensive Agents May Aid Cognition in Elderly
Memory recall better for up to 3 years with blood-brain barrier-crossing renin-angiotensin drugs versus nonpenetrant counterparts
More Bleeding Events After PCI in Women With Baseline Risk Factors
The researchers explored the association of sex with outcomes among patients treated with ticagrelor monotherapy vs ticagrelor plus aspirin.
Stroke Risk Up for Offspring of Moms With Hypertension in Pregnancy
Link between maternal hypertension during pregnancy and ischemic heart disease in offspring did not persist in sibling analyses
Modifiable Cardiovascular Risk Factors Linked to Severity of COVID-19
Strategies that improve cardiovascular health may also improve outcomes for people following COVID-19
- Loading...
Loading...
Next post in Cardiovascular Disease (CVD)
Loading... 
Loading...